# A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

> **NCT05128591** · PHASE1 · COMPLETED · sponsor: **Addpharma Inc.** · enrollment: 38 (actual)

## Conditions studied

- Embolism and Thrombosis

## Interventions

- **DRUG:** Rivaroxaban 18mg Oral Tablet
- **DRUG:** Rivaroxaban 20 MG Oral Tablet

## Key facts

- **NCT ID:** NCT05128591
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-09
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05128591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05128591, "A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05128591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*